Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.45 USD 2.3% Market Closed
Market Cap: 4.7B USD

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 35.06 USD. Compared to the current market price of 28.45 USD, Alkermes Plc is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
35.06 USD
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
68
Median 3Y
3.2
Median 5Y
3.3
Industry
7.8
Forward
3.1
vs History
34
vs Industry
9
Median 3Y
13.9
Median 5Y
-27.1
Industry
24.1
Forward
18.9
vs History
92
vs Industry
12
Median 3Y
11.5
Median 5Y
24.2
Industry
21.8
vs History
84
vs Industry
3
Median 3Y
12.5
Median 5Y
16.3
Industry
23.8
vs History
96
vs Industry
25
Median 3Y
3.6
Median 5Y
3.6
Industry
3.3
vs History
84
vs Industry
61
Median 3Y
2.6
Median 5Y
2.8
Industry
8
Forward
2.4
vs History
87
vs Industry
62
Median 3Y
3.1
Median 5Y
3.4
Industry
10.3
vs History
52
vs Industry
11
Median 3Y
8.7
Median 5Y
9.3
Industry
6.3
Forward
9.3
vs History
30
vs Industry
10
Median 3Y
9.7
Median 5Y
-24
Industry
6.7
Forward
13.7
vs History
93
vs Industry
13
Median 3Y
9.4
Median 5Y
21.5
Industry
7.9
vs History
84
vs Industry
9
Median 3Y
10.4
Median 5Y
12.8
Industry
6.3
vs History
57
vs Industry
34
Median 3Y
3.3
Median 5Y
3.2
Industry
5.5

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
4.7B USD 3.1 13.8 9.2 10
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
45B EUR 14.6 34.4 59.4 61.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 171.3
13.8
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 36.4
9.2
2%
4.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 41.9
10
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
61.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A